MaxCyte Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • MaxCyte's estimated annual revenue is currently $32.3M per year.(i)
  • MaxCyte received $1.7M in venture funding in December 2014.
  • MaxCyte's estimated revenue per employee is $280,522
  • MaxCyte's total funding is $31.3M.
  • MaxCyte's current valuation is $793.5M. (January 2022}

Employee Data

  • MaxCyte has 115 Employees.(i)
  • MaxCyte grew their employee count by 14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





MaxCyte News

2020-11-09 - CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting

GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that its subsidiary CARMA Cell Therapies will share results of a detailed phenotypic and functional characterization of MCY-M11, its lead anti-mesothelin CAR-PBMC c ...

2021-04-20 - MaxCyte : 2020 Full Year Results

MaxCyte, Inc. ('MaxCyte' or the 'Company') MaxCyte Reports Final Results for the Year Ended 31 December 2020 Gaithersburg, Maryland -20 April 2021:MaxCyte (LSE: MXCT, MXCL, MXCN),a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today annou ...

2021-10-28 - MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

Nkarta to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of ...

12-Sep-19 - MaxCyte Announces Presentation at ICLE 2019

Gaithersburg, Maryland – 9 September 2019 – MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, ...

31-Aug-19 - The MaxCyte (LON:MXCT) Share Price Is Down 49% So Some Shareholders Are Getting Worried

Investors in MaxCyte, Inc. (LON:MXCT) have tasted that bitter downside in the last year, as the share price dropped 49%. That contrasts poorly ...

12-Sep-19 - MaxCyte, Inc. (AIM:MXCT) Piotroski F-Score of 2 In Focus

MaxCyte, Inc. (AIM:MXCT) has a Piotroski F-Score of 2 at the time of writing. The F-Score may help discover companies with strengthening ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

MaxCyte Funding

DateAmountRoundLead InvestorsReference
2004-03-25$10.7MBIntersouth PartnersArticle